Science and Technology

Archive | news

April 13, 2021

Bispecific Estrogen Receptor α Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library Screening

April 12th 2021|J.Med.Chem 2021|Bispecific Estrogen Receptor α Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library Screening Bispecific degraders (PROTACs) of ERα are expected to be advantageous over current inhibitors of ERα signaling (aromatase inhibitors/SERMs/SERDs) used to treat ER+ breast cancer. Information from DNA-encoded chemical library (DECL) screening provides a method to identify novel PROTAC […]

Continue Reading
April 1, 2021

Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement

Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of COVID-19 and potential future coronavirus outbreaks WARMINSTER, PA, WALTHAM, MA, MUNICH, GERMANY, April 1, 2021 — Arbutus Biopharma Corporation (NASDAQ: ABUS), X-Chem, Inc. (X-Chem) and Proteros biostructures GmbH (Proteros) announced today that they have entered […]

Continue Reading
February 2, 2021

X-Chem Enters into Multitarget Oncology Discovery Research Collaboration and License Agreement with Genentech

 Collaboration Includes Licensing of Preclinical Small Molecule Program  WALTHAM, Mass.; Feb. 2, 2021 (Business Wire) – X-Chem, Inc., a global leader in DNA-Encoded Library (DEL) technology to identify novel drug leads, announced today that it has entered into a research collaboration and license agreement with Genentech, a member of the Roche Group. The goal of […]

Continue Reading
January 26, 2021

X-Chem acquires IntelliSyn and sister company, AviSyn, to extend and streamline drug discovery service range

Acquisition allows X-Chem to offer a more comprehensive, integrated, screen-to-lead drug discovery process to pharma and biotech clients IntelliSyn’s Founder and CEO Jeffrey Albert to join X-Chem management team Waltham, Mass., US: Jan. 26, 2021 (Business Wire) – X-Chem, Inc. (X-Chem), the industry-leading provider of DNA-Encoded Library (DEL)-based discovery services, has acquired IntelliSyn, a Montreal-based […]

Continue Reading
January 6, 2021

Servier and X-Chem Announce Drug Discovery Collaboration in Neurological Diseases

Servier and X-Chem Announce Drug Discovery Collaboration in Neurological Diseases Paris and Waltham, Mass.; Jan. 6, 2021 (Business Wire) – Servier, a global pharmaceutical Group and X-Chem, Inc., a privately held drug discovery company announced today a partnership to identify and develop novel small molecules for the treatment of neurological disorders. Under the terms of […]

Continue Reading
October 1, 2020

Proteros Biostructures and X-Chem to offer Comprehensive Joint Target-to-Lead Drug Discovery Services

Munich, Germany and Waltham, Mass –October 1, 2020 – Proteros Biostructures GmbH (Proteros) and X-Chem, Inc. (X-Chem) announced today the launch of an alliance with the goal of offering Hit-Identification and Target-to-Lead drug discovery services based on their complementary technology platforms. The alliance combines Proteros’ strengths in protein sciences, structural biology (crystallography and CryoEM), and […]

Continue Reading
July 22, 2020

X-Chem Announces Achievement of Milestone In Orexia Collaboration

Waltham, Mass – July 22, 2020 – X-Chem, Inc. (X-Chem), the global leader in DNA-encoded small molecule library screening and drug discovery, announced today that it has met a key development milestone in its collaboration with Orexia Limited (Orexia), a company focused on developing orexin positive modulators using unique structure based drug design capabilities.

Continue Reading
June 11, 2020

Study Published in the Journal of Medicinal Chemistry Demonstrates the Power of Machine Learning to Unlock New Chemistry and Biology to Treat Disease

WALTHAM, Mass. – June 11, 2020 – X-Chem, Inc., the leader in DNA-encoded small molecule library screening, and ZebiAI Therapeutics, a drug discovery company unlocking new disease targets, today announced the publication of a large prospective study to evaluate the power of machine learning (ML) to accelerate and improve the drug discovery process. The study, […]

Continue Reading
June 3, 2020

GHO Capital Acquires X-Chem, the Leading Provider of DNA-Encoded-Library-Mediated Drug Discovery Services

London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in healthcare, announces the acquisition of X-Chem, Inc. (X-Chem), the industry-leading provider of DNA-Encoded Library (DEL)-based discovery services, from an affiliate of The Carlyle Group and Hellman & Friedman LLC.

Continue Reading